
|Videos|November 15, 2020
AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
Author(s)OT Staff Reports
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Rethinking macular hole surgery without gas tamponade
2
Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment
3
Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers
4
Retina World Congress 2026: Can vibration reduce pain during intravitreal injections?
5





















